1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Indication Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Drug Innovation / Key Development Trends

4. Key Success Factors

    4.1. Pipeline Assessment

    4.2. Disease Treatment Pathophysiology

    4.3. Key Regulations

    4.4. Disease Epidemiology

5. Global Market Demand (in Value or Size in US$ Mn) Analysis 2018-2022 and Forecast, 2023-2033

    5.1. Historical Market Value (US$ Mn) Analysis, 2018-2022

    5.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Market Background

    6.1. Macro-Economic Factors

        6.1.1. Global GDP Growth Outlook

        6.1.2. Global Healthcare Expenditure Outlook

    6.2. Forecast Factors – Relevance & Impact

        6.2.1. Expenditure on R&D by Pharmaceutical Companies

        6.2.2. Cost of Drugs

        6.2.3. Merger and Acquisitions

        6.2.4. Collaborative Agreements

    6.3. Value Chain

    6.4. Market Dynamics

        6.4.1. Drivers

        6.4.2. Restraints

        6.4.3. Opportunity Analysis

7. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Drug Type

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Drug Type, 2018-2022

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Type, 2023-2033

        7.3.1. Cholinesterase Inhibitors

        7.3.2. Antipsychotic Drugs

        7.3.3. Carbidopa-Levodopa

        7.3.4. Antidepressants

        7.3.5. Benzodiazepine

        7.3.6. Modafinil

    7.4. Market Attractiveness Analysis By Drug Type

8. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Indication

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2018-2022

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2023-2033

        8.3.1. Dementia with Lewy Bodies (DLB)

        8.3.2. Parkinson’s Disease (PD)

    8.4. Market Attractiveness Analysis By Indication

9. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Distribution Channel

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2018-2022

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Drug Stores

        9.3.4. Online Pharmacies

    9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2018-2022

    10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. Middle East and Africa (MEA)

        10.3.5. East Asia

        10.3.6. South Asia

        10.3.7. Oceania

    10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2018-2022 and Forecast 2023-2033

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        11.3.1. By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Drug Type

        11.3.3. By Indication

        11.3.4. By Distribution Channel

    11.4. Market Attractiveness Analysis

12. Latin America Market Analysis 2018-2022 and Forecast 2023-2033

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        12.3.1. By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Drug Type

        12.3.3. By Indication

        12.3.4. By Distribution Channel

    12.4. Market Attractiveness Analysis

13. Europe Market Analysis 2018-2022 and Forecast 2023-2033

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        13.3.1. By Country

            13.3.1.1. U.K.

            13.3.1.2. Germany

            13.3.1.3. France

            13.3.1.4. Italy

            13.3.1.5. Spain

            13.3.1.6. Russia

            13.3.1.7. Nordic

            13.3.1.8. Poland

            13.3.1.9. Rest of Europe

        13.3.2. By Drug Type

        13.3.3. By Indication

        13.3.4. By Distribution Channel

    13.4. Market Attractiveness Analysis

14. South Asia Market Analysis 2018-2022 and Forecast 2023-2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        14.3.1. By Country

            14.3.1.1. India

            14.3.1.2. Thailand

            14.3.1.3. Indonesia

            14.3.1.4. Malaysia

            14.3.1.5. Rest of South Asia

        14.3.2. By Drug Type

        14.3.3. By Indication

        14.3.4. By Distribution Channel

    14.4. Market Attractiveness Analysis

15. East Asia Market Analysis 2018-2022 and Forecast 2023-2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        15.3.1. By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Drug Type

        15.3.3. By Indication

        15.3.4. By Distribution Channel

    15.4. Market Attractiveness Analysis

16. Oceania Market Analysis 2018-2022 and Forecast 2023-2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        16.3.1. By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Drug Type

        16.3.3. By Indication

        16.3.4. By Distribution Channel

    16.4. Market Attractiveness Analysis

17. Middle East and Africa Market Analysis 2018-2022 and Forecast 2023-2033

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. Iran

            17.3.1.3. Israel

            17.3.1.4. Turkey

            17.3.1.5. Rest of Middle East and Africa

        17.3.2. By Drug Type

        17.3.3. By Indication

        17.3.4. By Distribution Channel

    17.4. Market Attractiveness Analysis

18. Emerging Countries Market Analysis 2018-2022 and Forecast 2023-2033

    18.1. Introduction

        18.1.1. Market Value Proportion Analysis, By Key Countries

        18.1.2. Global Vs. Country Growth Comparison

    18.2. China Market Analysis

        18.2.1. Introduction

        18.2.2. Market Value Proportion Analysis by Market Taxonomy

        18.2.3. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

            18.2.3.1. By Drug Type

            18.2.3.2. By Distribution Channel

            18.2.3.3. By Indication

        18.2.4. China Market – Competition Landscape

        18.2.5. China – Trade Analysis

    18.3. India Market Analysis

        18.3.1. Introduction

        18.3.2. Market Value Proportion Analysis by Market Taxonomy

        18.3.3. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

            18.3.3.1. By Drug Type

            18.3.3.2. By Distribution Channel

            18.3.3.3. By Indication

        18.3.4. India Market – Competition Landscape

    18.4. Brazil Market Analysis

        18.4.1. Introduction

        18.4.2. Market Value Proportion Analysis by Market Taxonomy

        18.4.3. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

            18.4.3.1. By Drug Type

            18.4.3.2. By Distribution Channel

            18.4.3.3. By Indication

        18.4.4. Mexico Market – Competition Landscape

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Competition Deep Dive

        19.2.1. Axovant Sciences Ltd.

            19.2.1.1. Overview

            19.2.1.2. Global Manufacturing Sites

            19.2.1.3. Drug Sales Footprint

            19.2.1.4. Key Financials

            19.2.1.5. Analyst Commentary

        19.2.2. BioArctic AB

            19.2.2.1. Overview

            19.2.2.2. Global Manufacturing Sites

            19.2.2.3. Drug Sales Footprint

            19.2.2.4. Key Financials

            19.2.2.5. Analyst Commentary

        19.2.3. Eisai Co., Ltd.

            19.2.3.1. Overview

            19.2.3.2. Global Manufacturing Sites

            19.2.3.3. Drug Sales Footprint

            19.2.3.4. Key Financials

            19.2.3.5. Analyst Commentary

        19.2.4. Sumitomo Dainippon Pharma Co., Ltd.

            19.2.4.1. Overview

            19.2.4.2. Global Manufacturing Sites

            19.2.4.3. Drug Sales Footprint

            19.2.4.4. Key Financials

            19.2.4.5. Analyst Commentary

        19.2.5. Jazz Pharmaceuticals, Inc.

            19.2.5.1. Overview

            19.2.5.2. Global Manufacturing Sites

            19.2.5.3. Drug Sales Footprint

            19.2.5.4. Key Financials

            19.2.5.5. Analyst Commentary

        19.2.6. Immungenetics AG

            19.2.6.1. Overview

            19.2.6.2. Global Manufacturing Sites

            19.2.6.3. Drug Sales Footprint

            19.2.6.4. Key Financials

            19.2.6.5. Analyst Commentary

        19.2.7. Noven Pharmaceuticals, Inc.

            19.2.7.1. Overview

            19.2.7.2. Global Manufacturing Sites

            19.2.7.3. Drug Sales Footprint

            19.2.7.4. Key Financials

            19.2.7.5. Analyst Commentary

        19.2.8. Eli Lilly and Company

            19.2.8.1. Overview

            19.2.8.2. Global Manufacturing Sites

            19.2.8.3. Drug Sales Footprint

            19.2.8.4. Key Financials

            19.2.8.5. Analyst Commentary

        19.2.9. Novartis AG

            19.2.9.1. Overview

            19.2.9.2. Global Manufacturing Sites

            19.2.9.3. Drug Sales Footprint

            19.2.9.4. Key Financials

            19.2.9.5. Analyst Commentary

        19.2.10. Pfizer Inc.

            19.2.10.1. Overview

            19.2.10.2. Global Manufacturing Sites

            19.2.10.3. Drug Sales Footprint

            19.2.10.4. Key Financials

            19.2.10.5. Analyst Commentary

        19.2.11. Bayer AG

            19.2.11.1. Overview

            19.2.11.2. Global Manufacturing Sites

            19.2.11.3. Drug Sales Footprint

            19.2.11.4. Key Financials

            19.2.11.5. Analyst Commentary

        19.2.12. Mylan NV

            19.2.12.1. Overview

            19.2.12.2. Global Manufacturing Sites

            19.2.12.3. Drug Sales Footprint

            19.2.12.4. Key Financials

            19.2.12.5. Analyst Commentary

        19.2.13. Sanofi AG

            19.2.13.1. Overview

            19.2.13.2. Global Manufacturing Sites

            19.2.13.3. Drug Sales Footprint

            19.2.13.4. Key Financials

            19.2.13.5. Analyst Commentary

        19.2.14. Teva Pharmaceutical Industries Limited

            19.2.14.1. Overview

            19.2.14.2. Global Manufacturing Sites

            19.2.14.3. Drug Sales Footprint

            19.2.14.4. Key Financials

            19.2.14.5. Analyst Commentary

        19.2.15. GlaxoSmithKline plc

            19.2.15.1. Overview

            19.2.15.2. Global Manufacturing Sites

            19.2.15.3. Drug Sales Footprint

            19.2.15.4. Key Financials

            19.2.15.5. Analyst Commentary

        19.2.16. Takeda Pharmaceutical Company Limited

            19.2.16.1. Overview

            19.2.16.2. Global Manufacturing Sites

            19.2.16.3. Drug Sales Footprint

            19.2.16.4. Key Financials

            19.2.16.5. Analyst Commentary

        19.2.17. Allergan plc

            19.2.17.1. Overview

            19.2.17.2. Global Manufacturing Sites

            19.2.17.3. Drug Sales Footprint

            19.2.17.4. Key Financials

            19.2.17.5. Analyst Commentary

        19.2.18. Janssen Pharmaceuticals, Inc.

            19.2.18.1. Overview

            19.2.18.2. Global Manufacturing Sites

            19.2.18.3. Drug Sales Footprint

            19.2.18.4. Key Financials

            19.2.18.5. Analyst Commentary

        19.2.19. Bausch Health Companies Inc.

            19.2.19.1. Overview

            19.2.19.2. Global Manufacturing Sites

            19.2.19.3. Drug Sales Footprint

            19.2.19.4. Key Financials

            19.2.19.5. Analyst Commentary

        19.2.20. Mallinckrodt Pharmaceuticals

            19.2.20.1. Overview

            19.2.20.2. Global Manufacturing Sites

            19.2.20.3. Drug Sales Footprint

            19.2.20.4. Key Financials

            19.2.20.5. Analyst Commentary

20. Assumptions and Acronyms Used

21. Research Methodology

Table 01 : Global Market Pipeline Assessment – Clinical Trials

Table 02: Global Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Drug Type

Table 03: Global Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Indication

Table 04: Global Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Distribution Channel

Table 05: Global Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Region

Table 06: North America Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Country

Table 07: North America Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Indication

Table 08: North America Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Drug Type

Table 09: North America Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Distribution Channel

Table 10: Latin America Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Country

Table 11: Latin America Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Indication

Table 12: Latin America Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Drug Type

Table 13: Latin America Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Distribution Channel

Table 14: Europe Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Country

Table 15: Europe Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Indication

Table 16: Europe Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Drug Type

Table 17: Europe Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Distribution Channel

Table 18: South Asia Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Country

Table 19: South Asia Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Indication

Table 20: South Asia Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Drug Type

Table 21: South Asia Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Distribution Channel

Table 22: East Asia Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Country

Table 23: East Asia Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Indication

Table 24: East Asia Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Drug Type

Table 25: East Asia Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Distribution Channel

Table 26: Oceania Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Country

Table 27: Oceania Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Indication

Table 28: Oceania Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Drug Type

Table 29: Oceania Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Distribution Channel

Table 30: MEA Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Country

Table 31: MEA Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Indication

Table 32: MEA Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Drug Type

Table 33: MEA Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Distribution Channel

Table 34: China Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Drug Type

Table 35: China Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Indication

Table 36: China Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Distribution Channel

Table 37: India Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Drug Type

Table 38: India Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Indication

Table 39: India Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Distribution Channel

Table 40: Brazil Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Drug Type

Table 41: Brazil Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Indication

Table 42: Brazil Market size (US$ Mn) Analysis 2018-2022 and forecast 2023-2033, By Distribution Channel

※参考情報 レビー小体型認知症（LBD）は、認知機能の低下だけでなく、幻覚やパーキンソン症状が特徴の神経変性疾患です。この疾患は、レビー小体と呼ばれる異常なタンパク質の沈着が脳に起こることで引き起こされます。レビー小体型認知症は、アルツハイマー病やパーキンソン病といった他の認知症と症状が重なる場合が多いですが、特有の症状を持つため、診断には慎重さが求められます。 治療については、レビー小体型認知症に対する具体的な治療薬は少なく、症状の軽減を目的とした対症療法が中心となります。一般的に用いられる薬剤には、ドネペジルやリバスチグミンといったコリンエステラーゼ阻害薬があります。これらの薬剤は、脳内でアセチルコリンの濃度を高めることによって、記憶や認知にかかわる機能を改善する効果が期待されています。 また、レビー小体型認知症においては、運動障害や心的症状の管理も重要です。パーキンソン症状には、レボドパなどのドーパミン補充療法が効果的ですが、レビー小体型認知症の場合は、幻覚を引き起こす可能性があるため、慎重に使用する必要があります。また、抗精神病薬の使用も考慮されますが、選択や用量には特に注意が必要です。特に、古典的な抗精神病薬は副作用が強いため、使用が避けられることが一般的です。 レビー小体型認知症における幻覚の管理には、低用量のリスペリドンやクエチアピンなどの新規抗精神病薬が用いられることがあります。これらの薬剤は、比較的副作用が少なく、特に幻覚が強い場合には有効とされています。しかし、抗精神病薬の使用には、患者個々の状態に応じた評価が必要であり、医師との十分な相談が求められます。 治療には薬物療法だけでなく、非薬物療法も重要な役割を果たします。認知症専門のリハビリテーションや作業療法、音楽療法、アートセラピーなどが有効な手段とされており、患者の生活の質を改善することに寄与します。特に、家族や介護者との連携が重要視され、環境調整や日常生活の支援を行うことが、患者のストレスを軽減し、安定した生活を送るために不可欠です。 最近では、レビー小体型認知症に関する研究が進み、新しい治療法の開発に期待が寄せられています。例えば、レビー小体をターゲットにした治療薬や、病態進行を遅らせることを目的とした治療戦略が模索されており、将来的には症状を根本的に改善する可能性も考えられています。 関連技術としては、脳画像診断技術の向上があります。MRIやPET（陽電子放射断層撮影）を使用することで、レビー小体型認知症の診断精度が向上し、早期発見が可能になると期待されています。また、人工知能（AI）を活用した診断支援システムの開発も進行中で、これにより診断の効率化や精度向上が見込まれています。 レビー小体型認知症は、進行性の疾患であり現在のところ根治治療は存在しませんが、適切な治療と支援により、患者の生活の質を向上させることは可能です。医療機関との連携を密にし、最新の情報をもとにした個別に合った治療法を選択することが、より良い生活を実現する鍵となります。患者自身やその家族、介護者も一緒に関わりながら、支え合いの中で新たな道を見つけていくことが大切です。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/